ATRX Stock Overview
Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Adhera Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.007 |
| 52 Week High | US$0.60 |
| 52 Week Low | US$0.0065 |
| Beta | -0.098 |
| 1 Month Change | -44.00% |
| 3 Month Change | -68.18% |
| 1 Year Change | -98.83% |
| 3 Year Change | -99.46% |
| 5 Year Change | -99.90% |
| Change since IPO | -99.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| ATRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -30.0% | -5.0% | -3.5% |
| 1Y | -98.8% | -1.7% | 20.2% |
Return vs Industry: ATRX underperformed the US Biotechs industry which returned -1.7% over the past year.
Return vs Market: ATRX underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| ATRX volatility | |
|---|---|
| ATRX Average Weekly Movement | 28.9% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ATRX's share price has been volatile over the past 3 months.
Volatility Over Time: ATRX's weekly volatility has decreased from 61% to 29% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 2 | n/a | adherathera.com |
Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson’s disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018.
Adhera Therapeutics, Inc. Fundamentals Summary
| ATRX fundamental statistics | |
|---|---|
| Market cap | US$87.75k |
| Earnings (TTM) | -US$4.61m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs ATRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATRX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$4.61m |
| Earnings | -US$4.61m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.42 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -41.2% |
How did ATRX perform over the long term?
See historical performance and comparison